Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.3999
-0.0050 (-1.23%)
At close: Oct 26, 2026, 4:00 PM EDT
0.4299
+0.0300 (7.50%)
Pre-market: Oct 27, 2026, 4:01 AM EDT
Pasithea Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
13.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 15.06K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Radiopharm Theranostics | 8.90M |
| TScan Therapeutics | 7.11M |
| Dyadic International | 3.80M |
| SeaStar Medical Holding | 1.71M |
| Daré Bioscience | 1.37M |
| Allarity Therapeutics | 345.00K |
| Vyome Holdings | 129.73K |
| Kiora Pharmaceuticals | 20.00K |
KTTA News
- 3 days ago - Pasithea Therapeutics announces PAS-004 data at ESMO - TheFly
- 3 days ago - Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 - GlobeNewsWire
- 6 days ago - Pasithea Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 6 weeks ago - Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference - GlobeNewsWire
- 6 weeks ago - Pasithea Therapeutics Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Pasithea Therapeutics Slides: Corporate presentation - Filings
- 7 weeks ago - Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics Quarterly report: Q2 2026 - Filings